Δευτέρα, 25 Μαρτίου 2019

Craniofacial Surgery

Lingual frenotomy in neonates: past, present, and future
Publication date: Available online 23 March 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): K. Ganesan, S. Girgis, S. MitchellAbstractDuring the last decade, increasing awareness of breastfeeding and its health benefits has not been reflected in the provision of lingual frenotomy in neonates with tongue-tie. This could be because of inconsistencies in our understanding of the importance and treatment of ankyloglossia. In this review, we discuss the current clinical guidance...
British Journal of Oral and Maxillofacial Surgery
Sat Mar 23, 2019 17:17
Peripheral facial palsy after bilateral sagittal split ramus osteotomy: case report
Publication date: Available online 22 March 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): Y. Shimada, Y. Kawasaki, Y. MaruokaAbstractBilateral sagittal split ramus osteotomy (BSSRO) is commonly used in orthognathic surgery. Although abnormal sensation in areas that are innervated by the inferior alveolar nerve is a well-known neurological complication of mandibular osteotomy, facial palsy is rare postoperatively. We present a case of peripheral facial palsy that developed...
British Journal of Oral and Maxillofacial Surgery
Sat Mar 23, 2019 17:17
Re: Comparison of clinical outcomes of treatment of dysfunction of the temporomandibular joint between conventional and ultrasound-guided arthrocentesis
Publication date: Available online 22 March 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): M.F. Şentürk, U. Gülşen
British Journal of Oral and Maxillofacial Surgery
Sat Mar 23, 2019 17:17
Delayed Diagnosis and Treatment of Cerebrospinal Fluid Leakage in Current Practice
As delayed diagnosis and treatment of cerebrospinal fluid (CSF) leakage are common in current practice, this study was performed to determine associated factors and discuss appropriate strategies to deal with these problems. A retrospective analysis of all cases of CSF leakage in our hospital from 2007 to 2018, including 41 patients with CSF rhinorrhea and 5 with CSF otorhinorrhea, was performed. Symptoms, associated diseases, misdiagnoses, history of skull base repair surgical, previous medical...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Craniofacial Skills: A 2-Site Validation of Assessments to Aid Plastic Surgery Resident Milestone Achievement in Technical Skills and Instrument Knowledge
Background: Plastic surgery evaluates residents on milestones. This study defines a model of education including pre and post-test assessments paired with didactics intended for evaluating residents in the unique technical skills of craniofacial surgery. Methods: At the first institution, instrument identification, and time/accuracy of burr hole placement, craniotomy, and plating on Saw Bones Craniofacial Models were tested before and after a 7.5-hour craniofacial orthognathic surgery workshop....
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Prediction of Minimally Conscious State with Brain Stem Reflexes in Unconscious Patients after Traumatic Brain Injury
Objective: To evaluate the predictive power of the brain stem reflexes (BSRs) for minimally conscious state in unconscious patients after traumatic brain injury. Materials and Methods: A total of 120 patients with duration of unconsciousness were enrolled in this study. BSRs were recorded 14 days after Traumatic brain injury, and classified into 3 grades. Predictors including BSRs, age, sex, Glasgow Coma Scale (GCS), and cause of injury were also analyzed, respectively. The outcome was divided...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
An Interdisciplinary Approach to Treatment of Adult Facial Arteriovenous Malformations: A Review of the Literature and A Single Institution's Experience With "Late" Surgical Resection and Aesthetic Reconstruction
Background: Arteriovenous malformations (AVMs) are high flow vascular anomalies that are difficult to manage given their high recurrence rate. At this time, the optimal treatment of AVMs involves embolization and surgical resection. However, few studies have examined patient outcomes after a delayed surgical resection approach. Methods: A retrospective chart review of all patients presenting to a single institution with vascular malformations from 2000 to 2016 was performed. Patients with...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Trends and Outcomes of Management of Mandibular Fractures
Introduction: the diversity of the causes of trauma produces different patterns of fractures depending on sociodemographics, lifestyle, industry, and outdoor activities. Mandibular fractures (MFs) are the commonest facial fractures. Reconstruction aims to restore the preinjury anatomy and function as much as possible. Aim of the study: to evaluate the demographics, etiologies, patterns, treatment modalities and outcomes of management of MFs in southern Egypt. Patients and Methods: records...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
The Natural Growth Rate of Skull Base Meningiomas Compared With Non-Skull Base Meningiomas
In the present study, the authors assessed the differences in natural growth rates between skull base and non-skull base meningiomas by meta-analysis. Studies investigating meningioma growth rate were compiled from PubMed, Embase, Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature database, and the China National Knowledge Infrastructure databases. A systematic review and meta-analysis of the collected literature were conducted using Stata 12.0 software. A total of 7 observational...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Endoscopic Medial Maxillectomy With Preservation of Inferior Turbinate: Assessing Results by Acoustic Rhinometry
Background: The aim of this study is to demonstrate the effectiveness of the Endoscopic Medial Maxillectomy technique with the preservation of the nasal anatomy and function of the inferior turbinate. Methods: From January 2005 to December 2016, the authors performed 27 Endoscopic Medial Maxillectomy with preservation of inferior turbinate on 26 patients. The most frequent pathologies diagnosed were inverted papillomas (13/27) and antrochoanal polyps (7/27). There were 21 primary lesions...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
The Second Division of Trigeminal Nerve for Corneal Neurotization: A Novel One-Stage Technique in Combination With Facial Reanimation
Corneal neurotization represents an effective surgical strategy to restore corneal sensibility in patients affected by neurotrophic keratopathy. Corneal sensibility is essential in preserving structure and function of the eye. Loss of corneal sensibility can lead to a degenerative condition of the cornea known as neurotrophic keratopathy. Moreover, patients suffering from facial palsy show failure of full eyelid closure resulting in chronic corneal exposure and subsequent progressive damage. ...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Medication-Related Osteonecrosis of the Jaw: The Use of Leukocyte-Platelet-Rich Fibrin as an Adjunct in the Treatment
Medication-related osteonecrosis of the jaw are bone exposures in the maxillofacial region that does not heal after 8 weeks from the observation of a health care provider in patients with history of the intake of antiresorptive agents and no previous irradiation of the craniofacial region. Initially attributed only to the intake of bisphosphonates they have later been associated also with the intake of other classes of antiresorptive medications. This retrospective study analyzed records from patients...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Measurements and Clinical Application of Anatomical Space for Transfrontal Pituitary Surgery Through Magnetic Resonance Imaging Reconstruction
Objective: This study aims to clarify the relative position of the normal important structures and anatomical spaces formed by the structures passed through during the transfrontal pituitary surgery, and discuss how to avoid some eloquent structures. Methods: A total of 120 cases of magnetic resonance imaging images from normal adult brains were selected as the object of study and divided into male and female groups. The important adjacent structures of the pituitary passed through during...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Use of Calcium Phosphate Cement for Repairing Bone Defects: Histomorphometric and Immunohistochemical Analyses
This study aimed to assess the repair of surgically created bone defects filled with blood clot, autogenous bone, and calcium phosphate cement, by histomorphometric and immunohistochemical analyses. Ten adult male rabbits were used. Three bone defects were prepared with an 8-mm diameter trephine bur in the parietal region of each animal and filled with blood clot (Group BC), autogenous bone (Group AB), and calcium phosphate bone cement (Group CPC). The animals were euthanized at 40 and 90 postoperative...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Use of Neutrophil, Eosinophil, Basophil, and Platelet to Lymphocyte Ratio to Predict Patient Satisfaction After Septoplasty Plus Inferior Turbinate Reduction
Aim: Investigation of the predictive value of neutrophil, platelet, eosinophil, and basophil to lymphocyte ratio (NLR, PLR, ELR, and BLR) in evaluation of patients' satisfaction of septoplasty + inferior turbinate reduction operations. Patients and Methods: Seventy-six patients who were operated because of nasal obstruction were enrolled in the study. They were invited to the hospital and asked to answer a modified nasal obstruction symptom evaluation (NOSE) survey to determine their degree...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Proposal of Standardization of Closure Techniques After Endoscopic Pituitary and Skull Base Surgery Based on Postoperative Cerebrospinal Fluid Leak Risk Classification
Postoperative cerebrospinal fluid (CSF) leak still represents the main limitation of endonasal endoscopic surgery. The aim of the study is to classify the risk of postoperative leak and to propose a decision-making protocol to be applied in the preoperative phase based on radiological data and on intraoperative findings to obtain the best closure. One hundred fifty-two patients were treated in our institution; these patients were divided into 2 groups because from January 2013 the closure technique...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Histologic and Radiographic Characteristics of Bone Filler Under Bisphosphonates
Background: Dental implants and bone augmentation are well-established procedures used for oral rehabilitation. There is an increasing interest in biological mediators used topically for prevention of bone resorption maybe enhancement of osseointegration of dental implants. The purpose of the manuscript is to describe preliminarily the effect of bisphosphonates on the ossification pattern of bone grafts in a rat model. Material and Methods: Twenty Wistar-derived male rats were divided into...
Journal of Craniofacial Surgery - Published Ahead-of-Print
Wed Mar 20, 2019 02:00
Outcomes of zygomatic complex reconstruction with patient-specific titanium mesh using computer-assisted techniques.
Publication date: Available online 23 March 2019Source: Journal of Oral and Maxillofacial SurgeryAuthor(s): Wen-Bo Zhang, Yao Yu, Chi Mao, Yang Wang, Chuan-Bin Guo, Guang-Yan Yu, Xin PengAbstractPurposeZygomatic complex defects after extensive maxillectomy can cause severe esthetic and functional deformities. Patient-specific titanium mesh fabricated using computer-assisted technique is a promising method for such midface reconstruction. The aim of this study was to evaluate the application and clinical...
ScienceDirect Publication: Journal of Oral and Maxillofacial Surgery
Sat Mar 23, 2019 14:06
Is it Cost Effective to Add an Intraoral Scanner to an Oral and Maxillofacial Surgery Practice?
Publication date: Available online 23 March 2019Source: Journal of Oral and Maxillofacial SurgeryAuthor(s): Cory M. Resnick, Michael Doyle, Carly E. Calabrese, Karl Sanchez, Bonnie L. PadwaAbstractPurposeIntraoral scanners (IOSs), which create digital "impressions" of dental arches, have become popular for prosthetic and orthodontic applications. Adoption in oral and maxillofacial surgery (OMS) practices has been slower, likely due to high implementation costs and low volume use. The purpose of this...
ScienceDirect Publication: Journal of Oral and Maxillofacial Surgery
Sat Mar 23, 2019 14:06

Clinical Trials News

OtiTopic Moves towards Its Clinical Phase with Dry Powder Inhalation of Aspirin to Reduce the Risk of Vascular Mortality in Patients with Suspected Acute Myocardial Infarction (Ml)
LOS ANGELES--(BUSINESS WIRE)--Extensive studies on the effects of Aspirin on human health have been conducted over the past 100 years. Cardiovascular diseases are one of the top causes of death in America among older adults. For the past couple of decades, daily low dose aspirin has been a primary agent used to manage and prevent cardiovascular disease. It was recommended that patients (men over 50, women over 60) should take a low aspirin dose daily to prevent heart attacks. However, recently
Business Wire Health: Clinical Trials News
00:33
Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the "NYSE") stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company's delay in filing its Annual
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 23:00
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
SUMMIT, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MS?src=hash" target="_blank"gt;#MSlt;/agt;--Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5...
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 22:30
Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 22:15
Physicians' Education Resource® Presents "Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know"
CRANBURY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CME?src=hash" target="_blank"gt;#CMElt;/agt;--Physicians' Education Resource® Presents "Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know"
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 21:39
Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance
BOSTON--(BUSINESS WIRE)--Gelesis announced clinical data from its pivotal GLOW study showing impact of Gelesis100 on patients with prediabetes and untreated diabetes.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 20:00
Partenariat historique entre l'Institut Weizmann des sciences et l'Institut Curie
PARIS--(BUSINESS WIRE)--L'Institut Weizmann des Sciences (Rehovot, Israël) et l'Institut Curie (Paris, France), deux grands instituts de recherche de renommée internationale, ont signé un partenariat historique, qui permettra à leurs équipes de collaborer étroitement pour améliorer les connaissances en sciences de la vie, notamment aux interfaces de la physique et de la chimie, et plus particulièrement sur le cancer. Une étape clé dans l'histoire de ces deux instituts qui collaborent depuis 15
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 18:54
Historic Partnership between the Weizmann Institute of Science and Institut Curie
PARIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cancer?src=hash" target="_blank"gt;#cancerlt;/agt;--Historic partnership between the Weizmann Institute of Science and Institut Curie in the field of life sciences, specifically in cancer research.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 18:54
CIRCULOGENE's Precision Genomic Profiling Technology Featured in Three AACR 2019 Abstracts
BIRMINGHAM, Ala.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AACR?src=hash" target="_blank"gt;#AACRlt;/agt;--CIRCULOGENE to present 3 abstracts at 2019 AACR meeting, including preliminary data on the clinical application of cfDNA patient mutational load.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 16:10
VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting
MALVERN, Pa.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/antibiotics?src=hash" target="_blank"gt;#antibioticslt;/agt;--VenatoRx will present VNRX-7145 during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 16:00
ImpediMed Announces PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons
CARLSBAD, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/ASBrS19?src=hash" target="_blank"gt;#ASBrS19lt;/agt;--PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 15:00
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
CHICAGO--(BUSINESS WIRE)--Xeris is presenting data on its developmental ready-to-use (RTU) room-temperature stable liquid glucagon at two medical conferences.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:45
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK's Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company's Chairman & CEO, on March 21, 2019, exercised 17,589,250 warrants with an exercise price of $1.9984 and 1,851,000 options with an exercise price of $2.1983, representing an aggregate cash exercise price of $39.2. In commenting on the exercise of the warrants and options, Dr. Soon-Shiong said the foll
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors
BEDFORD, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the election of Leslie J. Williams to the Board of Directors of the Company....
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
European Phase 3 Trial of Aimmune Therapeutics' AR101 Meets Primary Endpoint
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics' European phase 3 trial of AR101 for peanut allergy met its primary endpoint.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
F-star Presents New Data on its Tetravalent Bispecific Antibodies at the AACR 2019 Annual Meeting
CAMBRIDGE, England--(BUSINESS WIRE)--F-star, a clinical-stage biopharmaceutical company pioneering the development of novel tetravalent bispecific antibodies that target the immune system to fight cancer, today announces that new preclinical data on three immuno-oncology programmes will be presented at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, US, held from 29 March – 03 April 2019. Neil Brewis, CSO of F-star said "We are excited about this new preclinical da
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease 
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
Bioasis Technologies Inc. Announces Warrant Extension
GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. ("Bioasis" or the "Company") (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture Excha
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
Masimo Announces FDA Clearance of the Rad-67™ Pulse CO-Oximeter® with Next Generation SpHb® Spot-check Monitoring & rainbow® DCI®-mini Reusable Sensor
IRVINE, Calif.--(BUSINESS WIRE)--Masimo announces FDA clearance of the Rad-67™ Pulse CO-Oximeter® with Spot-check Next Generation SpHb® and the rainbow® DCI®-mini Reusable Sensor.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 14:00
IMV Inc. to Present at Two Upcoming Investor Conferences
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019. Details on each conference and presentation are as follows: •   Venue: Spring Investor Summit, being held April 1-2, 2019 • Date of Presentation: Monday, April 1 • Time: 8:30 a.m. ET • Location: JW Marrio
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 13:05
Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced that it will present five-year outcomes from a prospective, multicenter study showing that DecisionDx®-UM accurately predicts metastatic risk for patients with uveal melanoma and is used by physicians to make patient management decisions based on risk categories determined by the test. The study will be pre
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 13:00
AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. reports fourth quarter and fiscal year 2018 financial results and provides a business update.
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 13:00
Aerie Pharmaceuticals Announces Four Appointments
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David Ellis, Ph.D., as Director, Chemistry, reporting to Mitchell deLong, Ph.D., Aerie's Vice President of Chemistry. Dr. Ellis will be responsible for advancing
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 12:30
IONTAS named Small Business of the Year at Cambridge News Business Excellence Awards 2019
CAMBRIDGE, England--(BUSINESS WIRE)--IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has won 'Small Business of the Year' category at the Cambridge News Business Excellence Awards 2019. Marking their 26th year, the Awards highlight Cambridge's best business talent, with winners selected by a panel of experts encompassing a broad range of business expertise. The 'Small Business of the Year' category recognises IONTAS for achieving sustained growth,
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 12:00
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies announced today the appointment of Andrea van Elsas, Ph.D., as a new member of the Company's Scientific Advisory Board (SAB). Dr. van Elsas is an immuno-oncology expert with over 20 years of experience in advancing highly innovative oncology assets and currently serves as Chief Scientific Officer of Aduro Biotech. In his role on the SAB, Dr. van Elsas will support InteRNA's pipeline development efforts and in particular the positio
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 12:00
Diamond Pharma Services Supports Akcea Therapeutics in Gaining EU Regulatory Approval for WAYLIVRA Treatment for Familial Chylomicronaemia Syndrome (FCS)
HARLOW, England--(BUSINESS WIRE)--Diamond Pharma Services ("Diamond"), a leading technical services and regulatory affairs consulting group, has announced that it provided EU regulatory support to Akcea Therapeutics Ltd (Akcea), resulting in a positive Committee for Medicinal Products Human Use (CHMP) opinion for the grant of a Conditional Marketing Authorisation for WAYLIVRA Solution for Injection, the first authorised medicine for the treatment of FCS. Headquartered in Boston, MA, Akcea is a
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 11:30
QIAGEN unterstützt den Welttuberkulosetag mit bedeutenden Innovationen im Kampf gegen latente Tuberkulose
HILDEN, Deutschland & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat den jährlichen Welttuberkulosetag, der am 24 März 2019 begangen wird, zum Anlass genommen, sein verstärktes Engagement für Vorsorgeuntersuchungen und Behandlungen für latente Tuberkoloseinfektionen (TB) hervorzuheben, ein weit verbreitet Leiden, das in anfälligen Patienten zu einer aktiven TB-Erkrankung führen kann. QIAGEN investiert in verschiedene Bereiche, die mit einfache
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 09:55
イマーゴ・バイオサイエンシズ、オメガ・ファンドが主導する4000万ドルのシリーズB資金調達を発表
サンフランシスコ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 骨髄疾患に対する革新的な治療薬の開発に当たっている臨床段階のバイオテクノロジー企業イマーゴ・バイオサイエンシズは本日、ライフサイエンス企業の創出と同企業への投資に取り組む国際的な一流投資企業オメガ・ファンドが主導する4000万ドルのシリーズB資金調達を発表しました。本投資ラウンドに参加するその他の投資企業は、既存投資企業のFrazier Healthcare Partners、Amgen Ventures、MRL Ventures Fundに加え、HighLight Capital、Pharmaron、Greenspring Associatesです。オメガ・ファンドのDr. Dina Chaya が取締役会に加わり、Dennis Hennerは所有するファンドを代表して取締役会会長にとどまります。 イマーゴ・バイオサイエンシズの最高経営責任者(CEO)であるHugh Young Rienhoff, Jr.(M.D.)は、次のように述べています。「イマーゴ・バイオサイエンシズは、投資コミュニティーからの関
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 07:39
Axcella Appoints Shreeram Aradhye, M.B.B.S., M.D., as Executive Vice President, Chief Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AXAcandidates?src=hash" target="_blank"gt;#AXAcandidateslt;/agt;--Axcella Appoints Shreeram Aradhye, M.B.B.S., M.D., as Executive Vice President, Chief Development Officer
Business Wire Health: Clinical Trials News
Mon Mar 25, 2019 06:01
QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis
HILDEN, Germany & GERMANTOWN, Maryland--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24QGEN&src=ctag" target="_blank"gt;$QGENlt;/agt;--QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis
Business Wire Health: Clinical Trials News
Sun Mar 24, 2019 09:00
Healthy Adults (18-55) - San Antonio TX
ICON Early Phase Services is conducting a research study for healthy adults ages 18-55. This study is being done to test the effectiveness of an inactivated flu vaccine when exposed to another drug. Vital signs, ECGs, physical examinations and pregnancy, drug and alcohol screens will be performed. Blood and urine samples will also be obtained during this study. Participants will complete: 1 screening visit 3 consecutive overnights 8 outpatient visitsTo determine if you fully qualify, it will be necessary...
ClinicalConnection.com New Clinical Trials
Mon Mar 25, 2019 00:00
Alzheimers Disease - Miami FL
A study is looking for participants with early Alzheimer's disease or memory problems, with or without medication.--------------------------------------------------------------------------------------------------------------------------------------------------Un estudio busca participantes con diagnostico de Alzheimer's temprano o problemas de memoria, con o sin medicamentos
ClinicalConnection.com New Clinical Trials
Fri Mar 22, 2019 00:00
Endometriosis - Miami FL
Study for women suffering from Endometriosis with heavy bleeding. Surgery or laparoscopy diagnosis is needed - Mujeres con endometriosis con sangrado abundante 
ClinicalConnection.com New Clinical Trials
Fri Mar 22, 2019 00:00
Janssen seeks expanded use of Darzalex combination therapy for patients with newly diagnosed ASCT multiple myeloma
"Today's submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma," said José Antonio Burón Vidal, VP Medical The post Janssen seeks expanded use of Darzalex combination therapy for patients with newly diagnosed ASCT multiple myeloma appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 25, 2019 14:03
Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn
Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy. The post Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 25, 2019 10:12
bluebird bio opens gene and cell therapy manufacturing facility in North Carolina
Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in a ribbon cutting ceremony at the 125,000-square-foot facility. Currently, The post bluebird bio opens gene and cell therapy manufacturing facility in North Carolina appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 25, 2019 10:12
Editorial Board
Publication date: April 2019Source: Contemporary Clinical Trials, Volume 79Author(s):
ScienceDirect Publication: Contemporary Clinical Trials
Sun Mar 24, 2019 13:09

Δημοφιλείς αναρτήσεις